Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual-Acting Angiotensin Receptor-Neprilysin Inhibitor (ARNi) von Gu, Jessie, Noe, Adele, Chandra, Priya, Al-Fayoumi, Suliman, Ligueros-Saylan, Monica, Sarangapani, Ramesh, Maahs, Suzanne, Ksander, Gary, Rigel, Dean F., Jeng, Arco Y., Lin, Tsu-Han, Zheng, Weiyi, Dole, William P.

Volltext

Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy von Singer, Jack W, Fleischman, Angela, Al-Fayoumi, Suliman, Mascarenhas, John O, Yu, Qiang, Agarwal, Anupriya

Volltext

Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures von Singer, Jack W, Al-Fayoumi, Suliman, Taylor, Jason, Velichko, Sharlene, O'Mahony, Alison

Volltext

Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies von Verstovsek, Srdan, Odenike, Olatoyosi, Singer, Jack W, Granston, Tanya, Al-Fayoumi, Suliman, Deeg, H Joachim

Volltext

Abstract 2602: The nonclinical toxicology profile of pacritinib, a JAK2FLT3 inhibitor with no dose-limiting clinical myelosuppression von Watson, Rebecca, Al-Fayoumi, Suliman

Volltext

Abstract 2602: The nonclinical toxicology profile of pacritinib, a JAK2/FLT3 inhibitor with no dose-limiting clinical myelosuppression von Watson, Rebecca, Al-Fayoumi, Suliman

Volltext

Abstract 10372: A Clinical Drug-Drug Interaction Study of Imb-1018972, a Novel Investigational Cardiac Mitotrope in Phase 2 Development for the Treatment of Myocardial Ischemia and... von Tremaine, Larry, Al-Fayoumi, Suliman, van de Wetering, Jeroen, van Iersel, Thjis, Patel, Jaikrishna, Chamberlin, Paul

Volltext

Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor von Singer, Jack W, Al-Fayoumi, Suliman, Ma, Haiching, Komrokji, Rami S, Mesa, Ruben, Verstovsek, Srdan

Volltext

Pharmacokinetics and Pharmacodynamics of Dexamethasone Sodium-m-Sulfobenzoate (DS) after Intravenous and Intramuscular Administration: A Comparison with Dexamethasone Phosphate (DP... von Hochhaus, Günther, Barth, Jürgen, Al-Fayoumi, Suliman, Suarez, Sandra, Derendorf, Hartmut, Hochhaus, Renate, Möllmann, Helmut

Volltext

MPN-302 Thorough QT Analysis of a Single Dose of Pacritinib: Results of the PAC107 Study von Buckley, Sarah, Al-Fayoumi, Suliman, Wang, Lixia, Dean, James, Suthar, Purvi, Kaufmann, Priska

Volltext

Thorough QT Analysis of a Single Dose of Pacritinib: Results of the PAC107 Study von Buckley, Sarah, Al-Fayoumi, Suliman, Wang, Lixia, Dean, James, Suthar, Purvi, Kaufmann, Priska

Volltext

AI & experimental-based discovery and preclinical IND-enabling studies of selective BMX inhibitors for development of cancer therapeutics von Elsanhoury, Rwan, Alasmari, Abdulaziz, Parupathi, Prashanth, Jumaa, Mouhannad, Al-Fayoumi, Suliman, Kumar, Avinash, Khashan, Raed, Nazzal, Sami, Fayyad, Ahmed Abu

Volltext

Identification of stabilized dynorphin derivatives for suppressing tolerance in morphine-dependent rats von Al-Fayoumi, Suliman I, Brugos, Boglarka, Arya, Vikram, Mulder, Esther, Eppler, Barbel, Mauderli, Andre P, Hochhaus, Günther

Volltext

Pilot study of the antifibrotic effects of the multikinase inhibitor pacritinib in a mouse model of liver fibrosis von Al-Fayoumi, Suliman, Hashiguchi, Taishi, Shirakata, Yuka, Mascarenhas, John, Singer, Jack W

Volltext

Abstract CT159: Investigation of the absorption, metabolism, excretion, and mass balance of [14C]-pacritinib in healthy subjects: a phase I study von Al-Fayoumi, Suliman, Amberg, Sherri, Zhou, Huafeng, Millard, Lindsey, Singer, Jack W., Dean, James P.

Volltext

Abstract CT159: Investigation of the absorption, metabolism, excretion, and mass balance of 14C-pacritinib in healthy subjects: a phase I study von Al-Fayoumi, Suliman, Amberg, Sherri, Zhou, Huafeng, Millard, Lindsey, Singer, Jack W, Dean, James P

Volltext

Clinical Pharmacology Profile of Pacritinib (PAC), a Novel JAK2/FLT3 Inhibitor von Al-Fayoumi, Suliman, Campbell, Mary S., Amberg, Sherri, Zhou, Huafeng, Millard, Lindsey, Dean, James P.

Volltext

Comprehensive Kinase Profile of Pacritinib, a Non-Myelosuppressive JAK2 Kinase Inhibitor in Phase 3 Development in Primary and Post ET/PV Myelofibrosis von Singer, Jack, Al-Fayoumi, Suliman, Ma, Haiching, Komrokji, Rami S, Mesa, Ruben, Verstovsek, Srdan

Volltext

Tolerability and toxicological profile of pixantrone (Pixuvri®) in juvenile mice. Comparative study with doxorubicin von Longo, Monica, Torre, Paola Della, Allievi, Cecilia, Morisetti, Alberto, Al-Fayoumi, Suliman, Singer, Jack W.

Volltext

Exposure-Response Analysis For Pacritinib (SB1518), a Novel Oral JAK2/FLT3 Inhibitor, In Patients With Myelofibrosis von Al-Fayoumi, Suliman, Wang, Lixia, Li, Hanbin, Wada, Russ, Dean, James P.

Volltext